Chris Vermeulen, founder and chief investment officer of the The Technical Traders, joins Small Caps to discuss the latest outlook for the markets based on technical analysis.

Chris Vermeulen, founder and chief investment officer of the The Technical Traders, joins Small Caps to discuss the latest outlook for the markets based on technical analysis.

Small Caps is Australia's #1 site for investor news & information on ASX listed small cap companies. The podcast keeps investors informed by showcasing interviews with directors of ASX listed small cap companies and financial market analysts. For more information visit: https://smallcaps.com.au/.

Small Caps is Australia's #1 site for investor news &amp; information on ASX listed small cap companies. The podcast keeps investors informed by showcasing interviews with directors of ASX listed small cap companies and financial market analysts. For more information visit: https://smallcaps.com.au/.

The Small Caps podcast keeps stock market investors informed with the latest news by interviewing directors of ASX listed small cap companies and financial market analysts.

Small Caps

Small Caps is Australia's #1 site for investor news & information on ASX listed small cap companies.

The podcast keeps investors informed by showcasing interviews with directors of ASX listed small cap companies and financial market analysts.

For more information visit: https://smallcaps.com.au/

Chris Vermeulen: warning bells are ringing in the stock market

RocketBoots (ASX: ROC) chief executive officer Joel Rappolt joins Small Caps to discuss how the company's cutting-edge AI and machine learning technologies are reshaping profitability and customer service in the retail and banking sectors

RocketBoots leverages AI to optimise workforce planning and prevent loss, dramatically improving customer experiences and net promoter scores.

Joel shares insights into RocketBoots’ journey from their successful IPO to deploying transformative AI technologies in markets across the UK, EU and USA.

For more information on RocketBoots:
https://smallcaps.com.au/stocks/asx-roc/

RocketBoots (ASX: ROC) chief executive officer Joel Rappolt joins Small Caps to discuss how the company's cutting-edge AI and machine learning technologies are reshaping profitability and customer service in the retail and banking sectors
RocketBoots leverages AI to optimise workforce planning and prevent loss, dramatically improving customer experiences and net promoter scores.
Joel shares insights into RocketBoots’ journey from their successful IPO to deploying transformative AI technologies in markets across the UK, EU and USA.
For more information on RocketBoots: https://smallcaps.com.au/stocks/asx-roc/

RocketBoots (ASX: ROC) unveils AI strategy to revolutionise the retail and banking sector (w/ Joel Rappolt)

Gerald Celente, founder of the Trends Research Institute and Trends Journal magazine, joins Small Caps to discuss the current events that are forming future trends.

With a 40-year track record of identifying, tracking and forecasting trends, Gerald is renowned as the world's #1 trend forecaster.

Topics discussed include: WW3, gold and silver, the office building bust and banks, the levels of debt, AI and much more..

Gerald Celente, founder of the Trends Research Institute and Trends Journal magazine, joins Small Caps to discuss the current events that are forming future trends.
With a 40-year track record of identifying, tracking and forecasting trends, Gerald is renowned as the world's #1 trend forecaster.
Topics discussed include: WW3, gold and silver, the office building bust and banks, the levels of debt, AI and much more..

Gerald Celente: World War 3 has begun, gold headed to $3,000

Anatara Lifesciences (ASX: ANR) executive chair Dr David Brookes joins Small Caps to discuss the progress of the company's trial of a potential treatment for the aptly named irritable bowel syndrome (IBS).

The company recently received the go-ahead to enrol patients for the second stage of its pivotal GaRP-IBS trial, which is to be conducted at 5 sites in Melbourne, Sydney and Brisbane.

Anatara has received highly encouraging findings from Stage 1 of the GaRP-IBS clinical trial and Stage 2 of the trial will progress these promising developments to further efficacy claims .

Under the trial guidelines, participants will be randomly placed into two groups to take either the optimum dose of the GaRP product selected from Stage 1 or the placebo.

It is expected that each patient will take approximately three months to complete the trial, which involves a wash-out period and then 8 weeks on the product or placebo.

While IBS is a fairly common issue, with an estimated 5% to 10% of the world's population currently be suffering from the syndrome, many of those people may well be unaware of what the issue is.

April is annual IBS Awareness Month with the aim this year to help destigmatise the different types of syndrome people may be suffering.

Approximately 1 in 5 Australians experience the unpleasant symptoms of irritable bowel syndrome (IBS) at some time.

Articles:
https://smallcaps.com.au/anatara-lifesciences-garp-therapy-trial-extension-treat-irritable-bowel-syndrome/
https://smallcaps.com.au/ibs-awareness-month-anatara-lifesciences-trial-offers-hope-millions/

For more information on Anatara Lifesciences:
https://smallcaps.com.au/stocks/asx-anr/

Anatara Lifesciences (ASX: ANR) executive chair Dr David Brookes joins Small Caps to discuss the progress of the company's trial of a potential treatment for the aptly named irritable bowel syndrome (IBS).
The company recently received the go-ahead to enrol patients for the second stage of its pivotal GaRP-IBS trial, which is to be conducted at 5 sites in Melbourne, Sydney and Brisbane.
Anatara has received highly encouraging findings from Stage 1 of the GaRP-IBS clinical trial and Stage 2 of the trial will progress these promising developments to further efficacy claims .
Under the trial guidelines, participants will be randomly placed into two groups to take either the optimum dose of the GaRP product selected from Stage 1 or the placebo.
It is expected that each patient will take approximately three months to complete the trial, which involves a wash-out period and then 8 weeks on the product or placebo.
While IBS is a fairly common issue, with an estimated 5% to 10% of the world's population currently be suffering from the syndrome, many of those people may well be unaware of what the issue is.
April is annual IBS Awareness Month with the aim this year to help destigmatise the different types of syndrome people may be suffering.
Approximately 1 in 5 Australians experience the unpleasant symptoms of irritable bowel syndrome (IBS) at some time.
Articles: <a href="https://smallcaps.com.au/anatara-lifesciences-garp-therapy-trial-extension-treat-irritable-bowel-syndrome/">https://smallcaps.com.au/anatara-lifesciences-garp-therapy-trial-extension-treat-irritable-bowel-syndrome/</a> <a href="https://smallcaps.com.au/ibs-awareness-month-anatara-lifesciences-trial-offers-hope-millions/">https://smallcaps.com.au/ibs-awareness-month-anatara-lifesciences-trial-offers-hope-millions/</a>
For more information on Anatara Lifesciences: <a href="https://smallcaps.com.au/stocks/asx-anr/">https://smallcaps.com.au/stocks/asx-anr/</a>

Chris Vermeulen: warning bells are ringing in the stock market

In 1 playlist(s)

Small Caps

Social links

Follow podcast

Recent clips